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Summary
Background Hearing loss affects access to spoken language, which can affect cognition and development, and can 
negatively affect social wellbeing. We present updated estimates from the Global Burden of Disease (GBD) study on 
the prevalence of hearing loss in 2019, as well as the condition’s associated disability.
Methods We did systematic reviews of population-representative surveys on hearing loss prevalence from 1990 to 2019. 
We fitted nested meta-regression models for severity-specific prevalence, accounting for hearing aid coverage, cause, 
and the presence of tinnitus. We also forecasted the prevalence of hearing loss until 2050.
Findings An estimated 1·57 billion (95% uncertainty interval 1·51–1·64) people globally had hearing loss in 2019, 
accounting for one in five people (20·3% [19·5–21·1]). Of these, 403·3 million (357·3–449·5) people had hearing loss 
that was moderate or higher in severity after adjusting for hearing aid use, and 430·4 million (381·7–479·6) without 
adjustment. The largest number of people with moderate-to-complete hearing loss resided in the Western Pacific 
region (127·1 million people [112·3–142·6]). Of all people with a hearing impairment, 62·1% (60·2–63·9) were older 
than 50 years. The Healthcare Access and Quality (HAQ) Index explained 65·8% of the variation in national age-
standardised rates of years lived with disability, because countries with a low HAQ Index had higher rates of years lived 
with disability. By 2050, a projected 2·45 billion (2·35–2·56) people will have hearing loss, a 56·1% (47·3–65·2) 
increase from 2019, despite stable age-standardised prevalence.
Interpretation As populations age, the number of people with hearing loss will increase. Interventions such as 
childhood screening, hearing aids, effective management of otitis media and meningitis, and cochlear implants have 
the potential to ameliorate this burden. Because the burden of moderate-to-complete hearing loss is concentrated in 
countries with low health-care quality and access, stronger health-care provision mechanisms are needed to reduce 
the burden of unaddressed hearing loss in these settings.
Funding Bill & Melinda Gates Foundation and WHO.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Hearing loss is common and can negatively affect 
multiple aspects of an individual’s life when unad­
dressed or when individuals’ communication needs are 
unsupported. Auditory deprivation can detract from 
quality of life and access to spoken communication, 
which can impede development of child spoken 
language1 and contribute to the risk of dementia2 and 
cognitive decline in older ages.3 Deafness in early life 
when unaddressed is associated with poor literacy 
outcomes and reduced employment opportunities in 
later life. The emotional effects of hearing loss can 
include loneliness, isolation, depression, and anxiety.4–6 
In many countries, children with hearing loss rarely 
receive schooling7 and adults have a much higher 
unemployment rate compared with their hearing peers.8
The effect of hearing loss is broadly recognised by 
several stakeholders, including researchers, clinicians, 
policy makers, and people living with the condition.9 
Announced during the celebration of World Hearing 
Day 2019, the Lancet Commission on Global Hearing 
Loss aims to examine how to reduce the burden of 
hearing loss, convening expert working groups on 
prevention, policy, technology, and protection.10 Efforts 
from The Lancet are complemented by plans from WHO 
to release the first­ever world report on hearing. The 
report seeks to utilise best available evidence to present a 
consistent narrative on hearing loss and hearing health 
care, call attention to priorities and best practices for 
hearing health care, and describe trends in the global 
distribution of hearing loss.11 Initiatives from researchers 
and other key decision makers underscore the relevance 
of hearing loss within the global health landscape and 
the condition’s effects.
Researchers have called for urgent multi­disciplinary 
action on hearing health care, including comprehensive 
screening programmes, increased access to hearing 
devices, and noise­reduction strategies.12 Despite the 
effects of hearing loss on spoken communication and 
wellbeing, literature on the prevalence of hearing loss is 
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relatively sparse, making the understanding of who is 
most affected and where resources should be allocated 
difficult.
The Global Burden of Diseases, Injuries, and Risk 
Factors (GBD) Study is a comprehensive attempt to 
quantify the contribution of hearing loss relative to other 
causes of ill health. The study provides annual data on 
the prevalence and associated levels of disability for 
369 diseases and injuries, as well as 87 risk factors. 
Estimates are updated annually, most recently for 
GBD 2019—the most recent GBD paper on hearing loss 
was based on GBD 2010 estimates.13 In this Article, we 
aimed to estimate the prevalence, severity, and dis­
tribution of global hearing loss and added forecasts of 
future disease prevalence through 2050.
Methods
Overview
The 2019 GBD produced estimates for 369 diseases 
and injuries; high­level methods have been described 
in detail elsewhere.14 Data for the prevalence and 
incidence of non­fatal conditions were pooled in 
DisMod­MR 2.1, a Bayesian meta­regression tool 
(described elsewhere).15
In addition to prevalence and incidence, GBD uses the 
years lived with disability (YLDs) metric to compare the 
morbidity associated with different non­fatal conditions. 
YLDs are calculated by multiplying the prevalence of a 
condition with its associated disability weight, reflecting 
the severity of that disease relative to all other health 
states. Disability weights range from 0 (meaning perfect 
health) to 1, which is equivalent to death.
This study complies with the Guidelines for Accurate 
and Transparent Health Estimates Reporting (GATHER) 
recommendations (appendix p 16).16
Definition of hearing loss
GBD defines hearing loss as the quietest sound an 
individual can hear in their better ear, taken as the 
pure­tone average of audiometric thresholds of 0·5 kHz, 
1 kHz, 2 kHz, and 4 kHz. Hearing loss is reported in the 
GBD by seven mutually exclusive severity categories 
(table 1).17 Two health states were assigned to each severity 
category on the basis of the presence of tinnitus, a ringing 
Research in context
Evidence before this study
The prevalence of hearing loss is estimated annually through the 
Global Burden of Disease (GBD) study, a systematic overview of the 
prevalence of 369 diseases and injuries. The latest GBD study on 
hearing loss was based on estimates from 10 years ago. Since then, 
we have obtained new sources of data through systematic reviews 
of population-representative studies, collaborator input, and 
additional targeted searches. Sources up to Dec 31, 2008, were 
obtained from a previously published systematic review. In GBD 
2013, we did a systematic review of sources published 2008–13 
onward using the following PubMed search string: “(hearing 
loss[Title/Abstract] OR deafness[Title/Abstract] OR hearing 
loss[Title/Abstract]) AND (prevalence[Title/Abstract]) AND 
(“2008”[PDAT] : “3000”[PDAT]) AND (cross sectional OR survey)”. 
In GBD 2016, we did an update systematic review of sources 
published between Nov 26, 2008, and Nov 30, 2016, using 
the following PubMed search string: “(hearing loss[Title/
Abstract] OR deafness[Title/Abstract] OR hearing loss[Title/
Abstract] OR audiometry[Title/Abstract]) AND 
(prevalence[Title/Abstract]) AND (“2008/11/26”[PDAT]: 
“3000”[PDAT]) AND (cross sectional OR survey)”, without 
any language restrictions. Sources that included self-
reported data, did not report hearing loss in the less severe 
ear, were not population representative, or did not report a 
definitive decibel-level threshold for reported hearing loss 
were excluded. Sources that reported bilateral hearing loss 
according to the GBD reference definition were included. 
Added value of this study
The GBD hearing loss paper published in 2010 was informed by 
42 studies in 29 countries. Our analysis provides an update that 
is informed by 215 survey sources from 77 countries. Method 
changes for the GBD 2019 iteration include new methods of 
adjusting data using non-standard hearing thresholds and 
splitting data with gender unspecified by sex. These GBD 
estimates are accompanied by forecasts of hearing loss 
prevalence until 2050, providing a comprehensive picture of 
current and future disease trends. We found that 1·57 billion 
people (95% uncertainty interval 1·51–1·64) had hearing loss 
in 2019, contributing to 43·45 million (29·68–61·80) years 
lived with disability as the third largest cause of disability in 
GBD. The global number of individuals with hearing loss is also 
projected to increase by 56·1% (47·3–65·2) in the next 30 years 
despite stable age-standardised prevalence.
Implications of all the available evidence
This study accompanies the 2021 WHO World Hearing Report, 
which describes the burden of hearing loss using the GBD 2019 
results and standards for ear and hearing care, and sets 
standards for policy and prevention. Our analysis provides 
evidence that hearing loss is largely caused by ageing, 
will increase in prevalence in coming years, and is more 
prevalent in countries with low health-care access. 
Cost-effective, preventive, and treatment interventions for 
hearing loss are available, including school-based screening 
programmes, hearing devices (eg, hearing aids or cochlear 
implants), and clinical management of ear disease. Health-care 
services must be prepared for large projected increases in 
burden, particularly in low-income and middle-income 
countries where ear specialists and audiologists are scarce.
See Online for appendix
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or buzzing in the ears that is associated with hearing loss.18 
Moderate­to­complete hearing loss consisted of all hearing 
loss greater than 35 dB and is most often associated with 
reduced functional outcomes in individuals.11 All hearing 
loss is defined as any hearing loss above 20 dB, ranging 
from mild to complete in severity.
This manuscript was produced as part of the GBD 
Collaborator Network and in accordance with the GBD 
Protocol.
Data processing
We used input data obtained via systematic reviews 
of epidemiological, population­representative surveys. 
Sources up to Nov 26, 2008, were obtained via a published 
system atic review, 19 and two additional systematic reviews 
done in 2013 and 2016 identified newer sources (appendix 
p 3). Sources were excluded that recorded self­reported 
hearing loss, were not population­representative, did not 
report bilateral (better ear) hearing loss, or did not use 
pure­tone audiometry to quantify hearing loss.
For data sources that reported prevalence by age and 
sex separately, we applied the proportion of female 
and male prevalence to age­specific data. We then ran a 
meta­regression on the log ratio of female and male 
prevalence in MR­BRT (meta­regression—Bayesian, 
regularised, trimmed; methodology has been described 
elsewhere14) and applied the model results to sex­split 
data reported for both sexes combined (appendix p 3).
Data sources that reported hearing loss by severity 
categories that differed from the GBD categories were 
adjusted using data from US National Health and 
Nutrition Examination surveys (NHANES).20 NHANES 
reported individual­level data on the exact decibel 
at which hearing loss was experienced. Adjustment 
factors were derived by running a meta­regression on 
the logit difference between the prevalence of the 
alternative and reference categories (appendix p 3). Data 
sources that reported prevalence in age groups larger 
than 20 years were split into 5­year age groups by 
applying the global age pattern of the GBD 2017 model.
Modelling strategy
To model hearing loss, we first ran three DisMod­MR 2.1 
models to estimate the prevalence of no hearing loss 
(0–19 dB), mild hearing loss (20–34 dB), and moderate­
to­complete hearing loss (≥35 dB). Socio­demographic 
Index (a summary measure of fertility, education, and 
gross domestic product)14 was used as a covariate in each 
model. These models were rescaled so that prevalence 
rates summed to one for each age, year, sex, and location. 
Lay description Range Disability weight (95% UI)
Normal Normal hearing 0–19 dB 0
Mild Has great difficulty hearing and understanding another person talking in a noisy place (eg, on an urban street) 20–34 dB 0·010 (0·004–0·019)
Mild with ringing Has great difficulty hearing and understanding another person talking in a noisy place (eg, on an urban street), and 
sometimes has annoying ringing in the ears
20–34 dB 0·021 (0·012–0·036)
Moderate Is unable to hear and understand another person talking in a noisy place (eg, on an urban street), and has difficulty hearing 
another person talking even in a quiet place or on the telephone
35–49 dB 0·027 (0·015–0·042)
Moderate with 
ringing
Is unable to hear and understand another person talking in a noisy place (eg, on an urban street), and has difficulty hearing 
another person talking even in a quiet place or on the telephone, and has annoying ringing in the ears for more than 5 min at 
a time, almost every day
35–49 dB 0·074 (0·048–0·107)
Moderately severe No lay description available 50–64 dB 0·092 (0·064–0·129)
Moderately severe 
with ringing
No lay description available 50–64 dB 0·167 (0·114–0·231)
Severe Is unable to hear and understand another person talking, even in a quiet place, and unable to take part in a telephone 
conversation; difficulties with communicating and relating to others sometimes cause emotional effects (eg, worry or 
depression)
65–79 dB 0·158 (0·104–0·227)
Severe with ringing Is unable to hear and understand another person talking, even in a quiet place, and unable to take part in a telephone 
conversation, and has annoying ringing in the ears for more than 5 min at a time, almost every day; difficulties with 
communicating and relating to others sometimes cause emotional effects (eg, worry or depression)
65–79 dB 0·261 (0·174–0·361)
Profound Is unable to hear and understand another person talking, even in a quiet place, is unable to take part in a telephone 
conversation, and has great difficulty hearing anything in any other situation; difficulties with communicating and relating 
to others often cause worry, depression, and loneliness
80–94 dB 0·204 (0·134–0·288)
Profound with 
ringing
Is unable to hear and understand another person talking, even in a quiet place, is unable to take part in a telephone conversation, 
has great difficulty hearing anything in any other situation, and has annoying ringing in the ears for more than 5 min at a time, 
several times a day; difficulties with communicating and relating to others often cause worry, depression, or loneliness
80–94 dB 0·277 (0·182–0·388)
Complete Cannot hear at all in any situation, including even the loudest sounds, and cannot communicate verbally or use a telephone; 
difficulties with communicating and relating to others often cause worry, depression, or loneliness
95+ dB 0·215 (0·143–0·307)
Complete with 
ringing
Cannot hear at all in any situation, including even the loudest sounds, and cannot communicate verbally or use a telephone, 
and has very annoying ringing in the ears for more than half of the day; difficulties with communicating and relating to 
others often cause worry, depression, or loneliness
95+ dB 0·316 (0·211–0·436)
Lay descriptions as listed were used in GBD disability weight surveys (appendix p 3). GBD=Global Burden of Disease. UI=uncertainty interval.
Table 1: Hearing loss health states, lay descriptions, thresholds on pure tone audiometry, and disability weights
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Second, we ran five DisMod models for the more severe 
levels of hearing loss and rescaled these to the prevalence 
of at least 35 dB hearing loss. Third, we ran one DisMod 
model for hearing aid coverage (defined as the proportion 
of individuals who use a hearing aid) and another for the 
proportion of hearing loss attributable to age­related or 
other factors. Uncertainty of final estimates was derived 
from the uncertainty in input data, data manipulations, 
and predictive covariates. We estimated uncertainty by 
running each model until convergence, then taking 
the 975th and 25th ordered draw from 1000 posterior 
model runs as 95% uncertainty intervals (UIs) for each 
point estimate.
Fourth, severity­specific prevalence of hearing loss was 
adjusted to account for hearing aid usage (appendix p 4). 
We calculated hearing aid coverage rates for each severity, 
age, sex, and location, using survey data and regression 
methods (appendix p 4). The identified proportion of 
individuals at each severity level who used a hearing aid 
were then shifted to the category directly below. Adjusted 
hearing loss refers to estimates that were adjusted 
downwards to account for hearing aid usage. By contrast, 
unadjusted hearing loss refers to estimates that were not 
adjusted downwards for hearing aid usage.
Fifth, we estimated the prevalence of hearing loss 
due to underlying causes—ie, chronic otitis media, 
congenital birth defects, meningitis, and age­related or 
other factors (appendix p 4). From birth to age 20 years, 
Age-standardised 
rate (95% UI)
Cases in millions 
(95% UI)
Hearing loss, ≥20dB
Global 19·3% (18·5–20·0) 1571·3 (1511·9–1635·5)
African region 18·9% (18·2–19·6) 136·7 (130·1–143·4)
Eastern Mediterranean 
region
14·9% (14·3–15·6) 78·8 (75·3–82·4)
European region 14·3% (13·7–15·0) 194·5 (185·4–204·0)
Region of the Americas 18·0% (17·3–18·9) 215·5 (205·9–225·6)
South-East Asia region 21·2% (20·4–22·0) 400·0 (385·2–415·8)
Western Pacific region 21·5% (20·7–22·3) 540·2 (519·6–562·0)
Moderate-to-complete hearing loss, ≥35 dB
Global 5·1% (4·5–5·6) 403·3 (357·3–449·5)
African region 5·4% (4·8–6·1) 38·7 (33·1–44·5)
Eastern Mediterranean 
region
4·7% (4·1–5·2) 21·3 (18·6–23·9)
European region 3·5% (3·1–3·9) 52·8 (46·2–59·6)
Region of the Americas 4·7% (4·2–5·3) 58·8 (51·7–66·2)
South-East Asia region 5·8% (5·2–6·5) 103·4 (90·9–115·4)
Western Pacific region 5·1% (4·5–5·7) 127·1 (112·3–142·6)
Mild hearing loss, 20–34 dB
Global 14·2% (13·6–14·8) 1167·9 (1116·4–1219·6)
African region 13·4% (12·8–14·0) 98·0 (93·4–102·5)
Eastern Mediterranean 
region
10·3% (9·8–10·7) 57·6 (54·8–60·4)
European region 10·8% (10·3–11·4) 141·7 (134·8–148·9)
Region of the Americas 13·3% (12·6–14·0) 156·7 (148·0–165·1)
South-East Asia region 15·3% (14·7–16·0) 296·6 (284·0–309·3)
Western Pacific region 16·4% (15·7–17·1) 413·2 (393·3–431·4)
Moderate hearing loss, 35–49 dB
Global 3·3% (2·9–3·8) 268·8 (235·5–302·4)
African region 3·2% (2·8–3·6) 22·5 (19·0–26·3)
Eastern Mediterranean 
region
3·0% (2·6–3·3) 13·6 (11·8–15·4)
European region 2·4% (2·1–2·7) 36·2 (31·4–41·3)
Region of the Americas 3·3% (2·9–3·7) 41·1 (35·9–46·3)
South-East Asia region 3·8% (3·4–4·3) 69·1 (60·1–78·0)
Western Pacific region 3·3% (2·9–3·7) 85·5 (75·0–96·9)
Moderately severe hearing loss, 50–64 dB
Global 1·1% (0·9–1·3) 85·0 (71·6–101·3)
African region 1·4% (1·2–1·6) 8·8 (7·3–10·6)
Eastern Mediterranean 
region
1·1% (0·9–1·3) 4·7 (3·9–5·5)
European region 0·7% (0·6–0·9) 11·8 (9·6–14·3)
Region of the Americas 0·9% (0·8–1·1) 11·7 (9·7–14·1)
South-East Asia region 1·3% (1·1–1·6) 21·9 (18·1–26·3)
Western Pacific region 1·0% (0·9–1·2) 25·8 (21·5–31·2)
(Table 2 continues in next column)
Age-standardised 
rate (95% UI)
Cases in millions 
(95% UI)
(Continued from previous column)
Severe hearing loss, 65–79 dB
Global 0·3% (0·2–0·3) 19·6 (15·8–24·1)
African region 0·5% (0·4–0·6) 3·7 (2·9–4·6)
Eastern Mediterranean 
region
0·3% (0·2–0·3) 1·2 (1·0–1·5)
European region 0·1% (0·1–0·2) 1·8 (1·4–2·3)
Region of the Americas 0·2% (0·2–0·2) 2·3 (1·8–2·9)
South-East Asia region 0·3% (0·2–0·3) 4·8 (3·8–6·0)
Western Pacific region 0·2% (0·2–0·3) 5·7 (4·5–7·1)
Profound hearing loss, 80–94 dB
Global 0·2% (0·2–0·3) 17·3 (13·7–21·5)
African region 0·2% (0·2–0·3) 2·0 (1·5–2·7)
Eastern Mediterranean 
region
0·2% (0·1–0·2) 1·1 (0·8–1·4)
European region 0·1% (0·1–0·2) 1·6 (1·3–2·0)
Region of the Americas 0·2% (0·1–0·2) 2·1 (1·7–2·7)
South-East Asia region 0·2% (0·2–0·3) 4·8 (3·7–6·1)
Western Pacific region 0·3% (0·2–0·3) 5·5 (4·4–6·9)
Complete hearing loss, ≥95 dB
Global 0·2% (0·1–0·2) 12·6 (10·3–15·5)
African region 0·2% (0·2–0·2) 1·7 (1·3–2·1)
Eastern Mediterranean 
region
0·1% (<0·1–0·1) 0·7 (0·5–0·8)
European region 0·1% (<0·1–0·1) 1·4 (1·1–1·7)
Region of the Americas 0·1% (0·1–0·2) 1·6 (1·3–1·9)
South-East Asia region 0·2% (0·1–0·2) 2·8 (2·2–3·5)
Western Pacific region 0·2% (0·2–0·2) 4·5 (3·7–5·5)
UI=uncertainty interval.
Table 2: Global and regional prevalent cases (in millions) and 
age-standardised prevalence by severity of hearing loss
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we scaled hearing loss prevalence due to congenital 
birth defects, otitis media, age­related and other factors, 
and meningitis to the total prevalence of each severity 
level. Above age 20 years, the difference between total 
hearing loss prevalence and hearing loss prevalence due 
to otitis media, meningitis, and congenital birth defects 
was assigned to age­related and other hearing loss.
Sixth, we estimated the prevalence of hearing loss with 
and without tinnitus (appendix p 5). We estimated the 
proportion of individuals with tinnitus using NHANES 
data, which reported the proportion of respondents with 
hearing impairment who experienced ringing, roaring, or 
buzzing. In the absence of cause­specific estimates of 
tinnitus, we assumed the same distribution across all 
causes. We applied proportions from NHANES data to 
our estimates to split hearing loss prevalence into 
prevalence with and without tinnitus.
Healthcare Access and Quality Indexand WHO regions
Results are presented by Healthcare Access and Quality 
(HAQ) Index as well as by WHO region. HAQ Index is 
a summary measure of the quality of national health 
systems that ranges from 0 to 100 and is based on 
analysis of avoidable deaths for 32 causes (methods 
described elsewhere).21
WHO member states are classified into six distinct 
regions: the Western Pacific region, South­East Asia 
region, European region, Region of the Americas, African 
region, and Eastern Mediterranean region (appendix p 6). 
Regional results in this paper are restricted to WHO 
member states and were produced in collaboration with 
WHO for the 2021 World Hearing Report.11
Forecasting global and regional hearing loss prevalence
Forecasts of hearing loss prevalence were generated 
using age­specific prevalence rates for the years 1990, 
1995, 2000, 2005, 2010, 2015, and 2019 as input data into 
a regression, with year, WHO region, and age as 
predictors. We included an interaction term between 
region and year and a cubic spline on age. Sex­specific 
regression models were run 1000 times, and the 
resulting coefficients were used to predict rates in the 
years 2030, 2040, and 2050. Predicted rates were 
multiplied by forecasted population for each WHO 
location to obtain case numbers, and then aggregated to 
obtain global estimates.22
Results
Source counts were calculated by summing all surveys 
that were considered for incorporation into the model, 
including those that were eventually excluded from the 
analysis (because of poor survey methodology, etc). We 
counted a survey reporting data from multiple countries 
as multiple data sources. In total, input data consisted 
of 215 survey sources in 77 countries (surveys were only 
counted once in the total summation, even if they were 
used in multiple aspects of hearing loss estimation). 
Modelling of hearing loss prevalence considered 113 sur ­
vey sources in 54 countries. Modelling of hearing aid 
coverage considered 100 survey sources in 44 countries. 
Other data came from ten data sources in two countries 
(data coverage and age­standardised coverage rates are 
shown in the appendix [pp 7, 9]).
An estimated 1·57 billion (95% UI 1·51–1·64) people 
had hearing loss in 2019, accounting for 20·3% (19·5–21·1) 
of the global population. Of these, 1·17 billion (1·12–1·22) 
people (74·3% [71·8–76·8]) had mild hearing loss. 
12·65 million (10·34–15·48) individuals had complete 
hearing loss. Without adjustment for hearing aid use, 
430·4 million (381·7–479·6) people globally had moderate­
to­complete hearing loss in the better­hearing ear.
Figure 1: Age-standardised YLD rates for all hearing loss 
(per 100 000 population) by HAQ Index
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Figure 2: Proportion of individuals with moderate-to-complete hearing loss 
by measure and severity
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Globally, the number of people with moderate­to­
complete hearing loss increased from 225·3 million 
(95% UI 197·6–250·9) in 1990, to 403·3 million 
(357·3–449·5) in 2019, a 79·1% (73·8–84·1) increase.
Age­standardised prevalence of moderate­to­complete 
hearing loss remained constant over the same period (age­
standardised prevalence for all hearing loss is presented in 
the appendix [p 9]), ranging from 5·8% (95% UI 5·2–6·5) 
in the South­East Asia region to 3·5% (3·1–3·9) in the 
European region. The largest number of people with 
moderate­to­complete hearing loss resided in the Western 
Pacific region (127·1 million [112·3–142·6]), the South­East 
Asia region (103·4 million [90·9–115·4]), and the region of 
the Americas (58·8 million [51·7–66·2]; table 2).
Between 1990 and 2019, the global number of YLDs 
attributable to hearing loss increased by 73·6% (95% UI 
67·1–79·2), from 25·02 million (16·96–35·34) to 
43·45 million (29·68–61·80). Of the YLDs attributed to 
hearing loss in 2019, 65·2% (52·5–76·6) were caused by 
moderate­to­complete cases and 34·8% (23·4–47·5) were 
caused by mild cases. In 2019, 7·00 million (4·76–10·06) 
YLDs were attributable to occupational noise exposure 
(appendix p 5).
The burden of all hearing loss is greatest at lowest 
levels of the HAQ Index, with a difference of more than 
3 times in YLD rates between countries with the lowest 
and highest HAQ Index values (figure 1). A linear 
regression analysis of age­standardised national YLD 
rates of hearing loss and HAQ Index found that HAQ 
Index explained 65·8% of the variation in YLD rates 
(adjusted r² 0·66).
Although 66·6% (95% UI 62·9–69·9) of moderate­
to­complete hearing loss cases were moderate in severity 
(35–49 dB), this severity accounted for 34·0% (26·2–42·6) 
of disability attributed to moderate­to­complete hearing 
loss (figure 2). Of all YLDs attributable to moderate­to­
complete cases, 34·0% (26·2–42·6) were attributable to 
moderate cases, followed by moderately severe (29·6% 
[25·6–33·8]), profound (13·6% [10·5–17·2]), severe (12·1% 
[9·7–14·8]), and complete cases (10·7% [8·3–13·6]).
Across the age spectrum, hearing loss was most severe 
in those approximately younger than 5 years and those 
older than 70 years, meaning that the proportion of 
cases that were moderately severe, severe, profound, 
or complete was much larger in these age groups 
(appendix p 10). Hearing loss was also more prevalent at 
older ages, most notably after age 50 years (figure 3). 
In 2019, 62·1% (95% UI 60·2–63·9) of all people 
with hearing impairment were older than 50 years, and 
4·4% (3·9–5·0) were younger than 15 years (69·7 million 
individuals [59·9–78·8]). Compared with other disease 
categories in the GBD, age­related and other hearing 
loss was the third largest cause of global YLDs in 2019, and 
the leading cause of global YLDs for individuals older than 
70 years. Full rankings are available at GBD Compare.
The cause of hearing loss changed from infections 
and congenital birth defects to other factors over age 
(figure 3). Under age 5 years, hearing loss was mostly 
attributable to otitis media (63·7% [95% UI 56·9–70·2]). 
By comparison, 96·2% (94·5–97·6) of hearing loss was 
attributable to age­related and other factors for adults 
aged 50–54 years.
Figure 3: Prevalence of hearing loss 35 dB or greater by age, severity, and cause
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Between 1990 and 2019, the crude prevalence rate of all 
hearing loss increased by 27·8% (95% UI 26·6–29·0), 
from 15·9% (15·3–16·6) in 1990 to 20·3% (19·5–21·1) 
in 2019. By contrast, the global age­standardised preva­
lence rate of all hearing loss remained stable, changing 
from 19·1% (18·4–19·9) in 1990 to 19·3% (18·5–20·0) 
in 2019. The increase in hearing loss cases while age­
standardised reates remained stable indicates that 
increases in prevalent cases are driven by population 
growth and ageing.
By 2050, a projected 2·45 billion (95% UI 2·35–2·56) 
people will have hearing loss, a 56·1% (47·3–65·2) 
increase from 2019, despite stable age­standardised 
prevalence (appendix p 15). An estimated 698·4 mil­
lion (617·7–777·8) people will have moderate­to­
complete hearing loss in 2050, with most people with 
moderate­to­complete hearing loss residing in the 
Western Pacific region (214·5 million [190·1–239·1]; 
figure 4). The greatest percentage increase is projected 
in the African region, where the number of those 
with moderate­to­complete hearing loss is predicted 
to increase from 38·70 million (33·08–44·47) to 
98·08 million (86·94–109·09), an increase of 154·9% 
(110·5–208·0). This region is followed by the Eastern 
Mediterranean region, where cases are projected to 
rise from 21·25 million (18·62–23·88) to 50·45 mil­
lion (43·84–57·59), a projected increase of 138·4% 
(96·7–184·8).
Discussion
Responsible for over 40 million YLDs, hearing loss was 
ranked as the third most common cause of YLDs in the 
GBD. Compared with other disease categories in the 
GBD, age­related and other hearing loss was the third 
largest cause of global YLDs in 2019 after low back pain 
and migraine, and was ranked first among sensory 
disorders. Age­related and other hearing loss was the 
leading cause of global YLDs compared with all causes 
that were explicitly modelled in the GBD for individuals 
older than 70 years.
Over 1·5 billion people live with hearing loss, 
403 million (26%) of whom have moderate­to­complete 
hearing loss in their better ear. All others have mild 
hearing loss. Although referred to as mild, such hearing 
loss can cause difficulties depending on its nature and 
the individual’s hearing needs.6,23 This effect is especially 
marked in children who are developing language skills 
and gaining education.23 Among adults, those with 
moderate­to­severe hearing loss in the better­hearing ear 
are most likely to benefit from clinical attention and 
interventions such as hearing aids.24 The burden of such 
hearing loss is concentrated mostly in low­income and 
middle­income countries, which exhibit higher age­
standardised rates of moderate­to complete­hearing 
loss compared with those of high­income countries. 
Moreover, the burden of disability attributable to hearing 
loss is concentrated in countries with poor health­care 
access, where hearing aid coverage is low and individuals 
are least likely to receive the care they need.
The distribution of individuals with moderate­to­
complete hearing loss varies across regions. Geo­
graphical variation could be attributable to several 
factors, including the prevalence of occupational noise 
exposure, preventable infections such as chronic otitis 
media and meningitis, and health­care access. A clear 
association exists between ageing and hearing loss, given 
that most of those with hearing loss are older than 
50 years. The progression of hearing loss with age also 
means that high­income countries have the highest 
all­age prevalence of hearing loss, driven mainly by their 
ageing population profile.
Although hearing loss is common in old ages, globally 
70 million children aged 0–15 years also live with this 
condition. Although the prevalence of hearing loss is 
low in children compared with in adults, hearing loss 
was most severe in both the youngest and oldest 
individuals. When unaddressed, childhood hearing loss 
can affect spoken language development, literacy skills,25 
and education, which might affect cognition and social 
wellbeing.4,6,8 These facts underline the importance of 
this affected population. Two of the causal factors that 
are responsible for hearing loss in children, otitis media 
and meningitis, are preventable. Our results align with 
WHO estimates that 60% of hearing loss in children is 
due to preventable causes such as ear infections and 
vaccine­preventable diseases.26
Figure 4: Prevalence of hearing loss 35 dB or greater, 1990–2019, with forecasts to 2050, by WHO region
Shading represents 95% UI. UI=uncertainty interval.
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The clear association between hearing loss and age 
means that nearly everyone, if they live long enough, will 
have some degree of hearing loss, and at least 50% will 
have moderate­to­complete hearing loss requiring 
intervention. As the world population grows and ages 
over the coming decades,22 the need for hearing care will 
rise. The results of this study anticipate that by 2050, 
698 million people will have moderate­to­complete 
hearing loss that could benefit from rehabilitation 
services. Rehabilitation services refer to comprehensive 
and holistic approaches that can include hearing aids 
and implants; rehabilitative therapy; sign language 
learning; other sensory substitutions like speechreading; 
and use of assistive technologies (eg, personal FM 
systems) and services (eg captioning). These inter­
ventions are detailed in the WHO world report on 
hearing.11 Although overall numbers are forecasted to be 
highest in the Western Pacific region in 2050, the greatest 
percentage increase is projected in the African region 
and the Eastern Mediterranean region.
Although hearing loss poses a substantial burden that 
will increase in coming years, methods of addressing 
this burden are available and cost­effective. Models 
indicate that passive screening in conjunction with 
hearing aid provision is an efficient intervention, with a 
cost of almost US$1000 per disability­adjusted life­year 
averted.27 GBD estimates suggest that there is an 
83% unmet need for hearing aids globally, calculated as 
the proportion of individuals with moderate­to­severe 
hearing loss who do not use a hearing aid.28 Other studies 
show that early rehabilitation along with use of hearing 
devices such as cochlear implants are also cost­effective, 
despite large costs associated with initial technology 
investments and the risks of infectious complications 
after implantation.29–31,33 For children with severe hearing 
loss, access to sign language and support for speech­
reading can improve access to education.32 The treatment 
of infections that can cause hearing loss (such as otitis 
media or meningitis) is similarly cost­effective, with 
variation in cost by treatment strategy.27 Although 
cost­effective interventions for hearing loss exist, they 
remain prohibitively expensive for health systems in low­
income and middle­income countries. These methods of 
reducing burden should be introduced to meet high 
need, accompanied by scale­up of health systems and 
universal health coverage for effective administration of 
interventions.
Our study was developed in close collaboration with 
WHO and links closely with its world report on hearing. 
This report further elaborates on the public health 
implications of the rising prevalence of hearing loss. 
With the figures and projections noted in our study as its 
basis, the world report outlines the framework of a global 
public health response that is focused on integrated 
people­centred ear and hearing care. By the use of 
available technological solutions with evidence­based 
public health approaches, hearing loss can be prevented, 
identified, treated, and rehabilitated, to curtail the 
condition’s projected increase in prevalence and over­
come the adverse affects on individuals and society. This 
approach includes cost­effective interven tions and 
strategies such as hearing screening for newborn babies, 
school­aged children, adults, and older adults as well as 
the use of hearing technology (eg, hearing aids or 
cochlear implants) and clinical management of ear 
diseases.27–31,33 Health­care services need to be prepared 
for the projected increases in burden, particularly in 
low­income and middle­income countries where ear 
specialists and audiologists are scarce.
We acknowledge the limitations of this study, most 
importantly the sparsity of the data on which these 
estimates are based. The lack of prevalence data is most 
marked in low­income countries, which have increased 
prevalence of severe hearing loss and insufficient access 
to audiometric technologies required for diagnosis. Data 
on hearing aid coverage is particularly sparse, with no 
severity­specific data outside of high­income countries 
and almost no data sources at all in Asia, north Africa, or 
Central Africa. This data gap might lead to overestimation 
of hearing aid coverage (and therefore underestimation 
of hearing loss prevalence) in low­income or under­
represented loca tions. Moreover, we exclusively relied on 
NHANES data to calculate severity adjustment factors 
for hearing loss prevalence and split prevalence by 
presence of tinnitus, neglecting geographical variation 
in the prevalence of hearing loss and tinnitus. Additional 
research is needed to gain a deeper understanding of 
hearing loss prevalence, concurrence with tinnitus, and 
hearing aid coverage in areas where data are limited.
Data on the causes of hearing loss are also sparse 
because few surveys report prevalence of hearing loss by 
underlying cause. This difficulty presents challenges 
because the causes of hearing loss differ substantially in 
children compared with in adults.26,34 Because more data 
exist on the cause of hearing loss in children, we scaled 
cause­specific hearing loss prevalence to total prevalence 
up to age 20 years. After this age, we treated age­related 
and other hearing loss as the residual between total 
prevalence and other causes of hearing loss. This residual 
approach has the potential to mask the contribution of 
other non­age factors to hearing loss burden. Moreover, 
other causes of hearing loss such as labour complications, 
vaccine­preventable diseases, non­occupational noise 
exposure, diabetes,35 and ototoxic medications such as 
amino glycosides were not accounted for in our estimates 
because of insufficient data. Strengthened data on the 
causes of hearing loss in older ages (as opposed to 
assuming that all hearing loss in old age is age­related) 
would improve this method.
Although meta­regression tools enable us to leverage 
information from data­rich locations to estimate 
prevalence in locations with no data, data sparsity can 
make distinguishing between true variation in prevalence 
and measurement error particularly difficult. This issue 
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is compounded by few predictive covariates or risk 
factors, because the association between hearing loss and 
other factors (like noise exposure) is not well quantified 
and likely to be masked by age. Data on self­reported 
hearing loss or audiometric data recorded with mobile 
technologies could potentially assess disease burden 
in locations where audiologists are sparse. However, 
telehealth methodologies are not yet widely used, and the 
generalisability of self­reported data is unclear.
GBD estimates of hearing loss are adjusted for hearing 
aid coverage, shifting the proportion of people with a 
hearing aid in each severity category to the category 
directly below. This adjustment might be crude in nature, 
masking the effect of hearing health care in reducing 
disability and neglecting variation in treatment effect 
between individuals. Whereas providers in eye care 
refer to best­corrected vision loss to mobilise resources 
towards those who are most amenable to treatment, no 
complementary best­corrected measure for hearing loss 
exists. Acquisition of data on best­corrected hearing loss 
could contribute to an understanding of the proportion 
of individuals with hearing loss who are amenable to 
intervention.
A systematic review of hearing loss prevalence will be 
completed for GBD 2020 to identify new sources of 
information in data­sparse locations. Additionally, we 
aim to revise modelling methods in upcoming years, 
assessing how prevalence is adjusted on the basis of 
hearing aid coverage, the proportion of individuals with 
hearing loss concurrent with tinnitus, and the severity 
distribution of hearing loss due to otitis media. We aim 
to forecast the avoidable burden of hearing loss with 
rapid implementation of hearing health­care inter­
ventions, provided additional data on intervention 
coverage is obtained. This forecast could provide policy 
makers with tools to effectively allocate hearing health­
care services and plan for future scenarios.
The results of this study point to a growing public 
health challenge, which needs global attention and a 
definitive response. The increasing prevalence of hearing 
loss, high contribution to global disability, and large 
unmet need for hearing aids together serve as a call for 
urgent attention. Cost­effective, preventive, and treatment 
solutions to mitigate the effects of hearing loss exist, 
including childhood screening programmes, earplugs 
and other noise­reduction technologies, hearing devices, 
and early treatment of otitis media and meningitis. 
Health system capacity must be scaled up to address 
growing needs, particularly in low­income settings.
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